PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6482787

Anaphylaxis.

M M Fisher
View original source ↗Export metadata ↓

Abstract

The clinical syndrome of anaphylaxis may be produced by a number of mechanisms. The life-threatening clinical features are angioneurotic oedema, bronchospasm, cardiovascular collapse and pulmonary oedema. The initial treatment consists of general resuscitation plus adrenaline. In shock, colloid solutions should be used to restore blood volume. The pulmonary oedema that occurs is a membrane oedema, and should be treated with artificial ventilation, positive end expiratory pressure, and volume replacement. After a reaction, all available tests should be used to determine the cause, and the patient should be given a warning letter describing the evidence for attributing his reaction to the determined cause. (This should be done in addition to the provision of any identification bracelet.) Pharmacological pretreatment is a valid preventive manoeuvre, but is not 100% reliable.

Explore related subjects

AminophyllineAnaphylaxisAnestheticsBronchial SpasmCardiopulmonary BypassEpinephrineHistamine AntagonistsHumansResuscitationJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M M Fisher. 1984-09-01. Anaphylaxis.. https://doi.org/10.5694/j.1326-5377.1984.tb133021.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Effects of short-term aminophylline administration on cardiac functional reserve in patients with syndrome X.

OBJECTIVES: This study sought to evaluate the effect of adenosine receptor blockade by aminophylline on cardiac functional reserve in patients with syndrome X. BACKGROUND: Aminophylline may have a potentially antiischemic effect through the inhibition of adenosine and, thus, the coronary steal phenomenon in patients with syndrome X. METHODS: A single-blind, placebo-controlled study of an intravenous infusion of aminophylline (6 mg/kg body weight over 15 min) or placebo (20 ml of saline solution over 15 min) was performed during continuous radionuclide monitoring of left ventricular ejection fraction in 12 patients performing supine bicycle ergometric exercise. RESULTS: Aminophylline increased exercise time (aminophylline 400 s vs. placebo 355 s, p < 0.01), decreased degree of ST segment depression (aminophylline 1.6 mm vs. placebo 2.4 mm, p < 0.01) and either abolished (seven patients) or diminished (five patients) chest pain during exercise. Aminophylline also increased left ventricular ejection fraction at rest (aminophylline 66.5% vs. placebo 62.3%, p < 0.05) but did not improve its deterioration at peak exercise (aminophylline 60.1% vs. placebo 56.6%, p = NS) or shorten the abnormally prolonged interval between the end of exercise and the overshoot (aminophylline 115 s vs. placebo 130 s, p = NS). CONCLUSIONS: Aminophylline infusion increases ischemic threshold and prolongs exercise duration in patients with syndrome X. It is hypothesized that aminophylline acts by inhibiting the coronary steal phenomenon through adenosine receptor blockade. It does not improve the deterioration in left ventricular function at peak exercise or the delayed response in ejection fraction in the recovery period, presumably because the beneficial effects of aminophylline that result from the redistribution of coronary blood flow are limited.

Aminophylline↗
PubMed1995

Aminophylline use in the critically ill: an old ally or new foe?

Although the use of aminophylline as a first line bronchodilator has declined during the last 2 decades, there are other clinical indications for which aminophylline is effective and may be the drug of choice. In this article, the author describes the drug's pharmacokinetics, physiologic effects, and indications for use. In addition, research pertaining to contemporary use of the drug is summarized. It is hoped that this article will help the critical care nurse assess and care for those critically ill patients for whom in aminophylline is used as primary or adjunctive therapy.

Aminophylline↗
PubMed1995

Aminophylline: could it act as an antioxidant in vivo?

Potential antioxidant properties of aminophylline and theophylline were investigated. We have found that these drugs, though ineffective against superoxide anion and hydrogen peroxide, are scavengers of hydroxyl radical (OH.). Indeed, second-order rate constants (k) of aminophylline and theophylline with OH. are about 1.9 x 10(10) mol-1 s-1 and 4.5 x 10(9) mol-1 s-1, respectively. Ethylenediamine, which is present in the aminophylline molecule, significantly contributes to this marked OH. scavenging activity, since it is characterized by a high k value, i.e. about 8 x 10(9) mol-1 s-1. However, when using therapeutically relevant concentrations of the methylxanthines (9 and 13 micrograms mL-1), significant antioxidant effects against OH.-induced oxidant injury are evident only with aminophylline. Although all three substances can apparently bind and inactivate iron, only aminophylline is effective at 9 and 13 micrograms mL-1; also this action is favoured by ethylenediamine. Moreover, therapeutic concentrations of aminophylline, but not of theophylline, are capable of antagonizing hypochlorous acid (HOCl); this effect is entirely due to the presence of ethylenediamine. Oxidant species, such as OH. and HOCl, have been implicated in the pathophysiology of asthma; it could be hypothesized, therefore, that some therapeutic effects of aminophylline may be related to its antioxidant properties, which are partly or totally attributable to ethylenediamine, depending on the chemical identity of the prooxidant antagonized (e.g. iron/OH. or HOCl). Aminophylline antioxidant capacity should be taken into account when investigating the lung epithelial lining fluid antioxidant capacity and oxidative stress indices in humans.

Aminophylline↗